Elite Pharmaceuticals Inc (OTCPK:ELTP)
$ 0.38 +0.0062 (+1.66%) Market Cap: 408.11 Mil Enterprise Value: 384.13 Mil PE Ratio: 18.95 PB Ratio: 4.12 GF Score: 60/100

Q2 2026 Elite Pharmaceuticals Inc Earnings Call Transcript

Nov 17, 2025 / 04:30 PM GMT
Release Date Price: $0.5814 (-13.87%)

Key Points

Positve
  • Elite Pharmaceuticals Inc (ELTP) reported a significant revenue increase of 92% for the quarter, reaching $36.3 million compared to $18.8 million in the same quarter last year.
  • The company's gross profit increased by 72% to $14.1 million, demonstrating strong financial performance.
  • Operating profits for the quarter rose by 136% to $8.2 million, indicating improved operational efficiency.
  • Elite Pharmaceuticals Inc (ELTP) has maintained a strong balance sheet with working capital increasing by 63% to $75 million.
  • The company has a robust pipeline with several new product launches planned, including ropinirole and methadone, which are expected to contribute to future growth.
Negative
  • Margins have decreased due to increased competition in the generic market, particularly for products like generic Vyvanse.
  • Revenues were down from the previous quarter, partly due to increased supply and downward pressure on prices.
  • Research and development expenses have declined, which may impact future innovation and product development.
  • General and administrative costs have increased significantly, rising to $4 million from $2.3 million in the same quarter last year.
  • The company faces challenges in maintaining market share amidst intense competition and pricing pressures in the generic pharmaceutical industry.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ELTP.PK - Elite Pharmaceuticals Inc
Q2 2026 Elite Pharmaceuticals Inc Earnings Call
Nov 17, 2025 / 04:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals second quarter of fiscal year 2026 conference call.

At this time all lines have been placed on a listen-only mode.

Before management begins speaking, the conference has the following statement.

Elie would like to remind the listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time, including, but not limited to statement about elite's expectations regarding forward operating results.

Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot